Spotlight session: Novel, redosable in vivo CAR platform for reprogramming multiple immune cell types against solid tumors

Velvet Therapeutics is advancing a novel in vivo CAR platform based on a biodegradable, lymphatic tropic branched polypeptide delivering minicircle DNA (mcDNA) to reprogram multiple immune cell types endogenously. The polypeptide can be readily scale-up in a two-step liquid phase synthesis while the mcDNA production is fully compatible with standard plasmid production process. Paired with Velvet’s CAR architecture designed to activate multiple cell types, this unique platform aims to address the unmet need in solid tumor indications.